Apollomics, Inc.

$13.84-2.54%($-0.36)
TickerSpark Score
60/100
Mixed
80
Valuation
40
Profitability
100
Growth
52
Health
30
Momentum

Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a APLM research report →

52-Week Range26% of range
Low $3.66
Current $13.84
High $42.12

Companywww.apollomicsinc.com

Apollomics, Inc. , a biotechnology company, engages in the discovery and development of oncology therapies to address unmet medical needs in California, Hangzhou, Shanghai, China, and Australia. It develops APL-101 (Vebreltinib), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other advanced tumors; APL-102 is an oral active, small molecule multiple tyrosine kinase inhibitor for liver cancer, breast cancer, and esophageal cancer; and APL-122, a tumor inhibitor candidate to treat cancers within the brain.

CEO
Hung-Wen Chen
IPO
2021
Employees
13
HQ
Foster City, CA, US

Price Chart

+159.66% · this period
$36.65$20.29$3.93May 20Nov 18May 20

Valuation

Market Cap
$15.27M
P/E
-0.53
P/S
1.80
P/B
-1.83
EV/EBITDA
-1.33
Div Yield
0.00%

Profitability

Gross Margin
0.00%
Op Margin
-111.45%
Net Margin
-128.69%
ROE
288.40%
ROIC
-1586.77%

Growth & Income

Revenue
$8.50M · 4192.93%
Net Income
$-10,939,000 · 79.69%
EPS
$-7.57 · 85.66%
Op Income
$-9,473,000
FCF YoY
63.96%

Performance & Tape

52W High
$42.12
52W Low
$3.66
50D MA
$15.71
200D MA
$16.12
Beta
1.52
Avg Volume
7.30K

Get TickerSpark's AI analysis on APLM

Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.

Get Pro Access →

30-day money-back guarantee · cancel anytime

Recent Insider Transactions

DateInsiderTypeShares
May 17, 26Huang Ya-Chiother500
May 17, 26Huang Ya-Chiother500
Mar 18, 26CHEN HONG-JUNGother0
Mar 31, 26CHEN HONG-JUNGother2,290
Mar 31, 26LIN PETER KUAN-HOWother3,582
Mar 18, 26Jan Chen-Huanother0
Mar 18, 26TSAI HSIEN-SHUother0
Mar 18, 26LIN PETER KUAN-HOWother0
Mar 19, 26Chen Hung-Wenother0
Mar 19, 26Chen Hung-Wenother0

Our APLM Coverage

We haven't published any research on APLM yet

For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.

Generate APLM Report →

Similar Companies